Oslo, Norway, 4 March 2016

Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology,
announces that the Board of Directors of Nordic Nanovector ASA ("Nordic
Nanovector" or the "Company") has decided to grant 510,000  share options in
accordance with the proxy given by the Annual General Meeting held on 9 March
2015. Each option, when exercised, can acquire one share in Nordic Nanovector.
The options are granted without consideration.

The options will expire after 7 years. The vesting schedule means that 25% of
each option holder's options will vest 12 months after the day of grant as long
as the option holder is still employed. Thereafter, 1/36 of the remaining
options will vest each month as long as the option holder is still employed,
with the first 1/36 vesting 13 months after the day of grant. The exercise price
of the options is NOK 14,24. The exercise price is equal to the volume weighted
average trading price of the shares of the Company quoted on the Oslo Stock
Exchange the last five days prior to the date of the grant.

Primary insiders that were granted options have the following holdings of
options and shares in the Company after the new share options were granted on 3
March 2016 (new options in parenthesis):

Luigi Costa, CEO holds 1,088,106 options (220,000) and owns 73,186 shares

Jostein Dahle, CSO holds 155,000 options (30,000) and owns 254,958 shares
including shares to related party

Anniken Hagen, CQO holds 155,333 options (30,000) and owns 48,771 shares

Tone Kvåle, CFO holds 240,000 options (35,000) and owns 139,854 shares including
shares to related party

Marco Renoldi, CBO holds 368,137 options (90,000) and owns 70,000 shares

The options allocated to the management of the Company is in accordance with the
Board of Director's Declaration on salaries and other remuneration to the senior
executive management, as approved by the Company's annual general meeting held 9
March 2015. The total number of outstanding share options is now 2,681,576,
equivalent to 5.7% of outstanding shares and options on a fully diluted basis.

###

For further information, please contact:

Luigi Costa, Chief Executive Officer

Cell: +41 79 124 8601

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76 Email: ir@nordicnanovector.com

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and
commercialisation of novel targeted therapeutics in haematology and oncology.
The Company's lead clinical-stage product opportunity is Betalutin®, the first
in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve
upon and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and orphan drug
opportunities, representing a growing market worth over $12 billion by 2018.

Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a
low intensity radionuclide (lutetium-177). The preliminary data has shown
promising efficacy and safety profile in an ongoing Phase 1/2 study in a
difficult-to-treat NHL patient population. The Company is aiming at developing
Betalutin® for the treatment of major types of NHL with first regulatory
submission anticipated in 1H 2019.

Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets, while exploring
potential distribution agreements in selected geographies. The Company is
committed to developing its ARC pipeline to treat multiple selected cancer
indications.

Further information about the Company can be found at www.nordicnanovector.com

